AbstractRemdesivir has been used for coronavirus disease 2019 (COVID‐19) pneumonia with oxygen requirements that do not require mechanical intubation, and several studies showed a reduction in disease duration. However, there is a concern about bradycardia as its side effect. We aimed to investigate the association between Remdesivir and bradycardia by integrating findings from prior studies. We queried PubMed and EMBASE in February 2023 and performed a meta‐analysis of studies investigating bradycardia in patients who did or did not receive Remdesivir. The outcome of interest was the rate of bradycardia and in‐hospital mortality. We identified eight studies involving 8993 patients, of which seven studies investigated bradycardia. Six studies were observational, one was a case–control, and one was a randomized trial. Incidence of bradycardia was 400/3480 patients (22.3%, 95% confidence interval, CI: [6.5–54.4], I² = 99%) in the Remdesivir group and 294/5005 (9.8%, 95% CI: [2.8–29], I² = 98.61) in the non‐Remdesivir group. The odds ratio of bradycardia was 2.11 (95% CI: [1.65–2.71], I² = 22%, p < 0.001) for the Remdesivir group. There was no difference in mortality between the two groups. Patients who received Remdesivir for COVID‐19 were more likely to develop bradycardia. The effect of confounding factors should be considered to further clarify the possible association.